Physician profile
James J Naramore
NPI 1841280880
$461.82
in general payments reported to CMS, 2019-2025
14 companies · $24.66 in 2025
The $24.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $38.57 · 2022: $92.11 · 2024: $50.51 · 2025: $24.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.25 | 2019-2020 | |
| Novo Nordisk INC | $60.79 | 2019 | |
| Saluda Medical Americas, INC. | $50.51 | 2024 | Evoke |
| Amgen INC. | $50.39 | 2019 | |
| Allergan, INC. | $27.01 | 2019 | |
| Hologic Sales and Service, LLC | $24.66 | 2025 | Aptima |
| Lilly USA, LLC | $24.25 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $14.92 | 2019 | |
| Pfizer INC. | $14.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.27 | 2020 | |
| Daiichi Sankyo INC. | $12.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.10 | 2019 | |
| Tactile Systems Technology INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Naramore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.